

paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute the following claims 68, 70, 79, 80, 86, 87, and 89 for the pending claims 68, 70, 79, 80, 86, 87, and 89:

E1
68. (Once Amended) A method for selecting a nucleic acid molecule encoding a target epitope of cytotoxic T-lymphocytes, comprising:

Sub H1
(a) contacting host cells with cytotoxic T-lymphocytes specific for said target epitope under conditions wherein a host cell expressing said target epitope undergoes a lytic event upon contact with said T-lymphocytes; wherein said host cells comprise a library of heterologous nucleic acid molecules, at least one of said heterologous nucleic acid molecules encoding said target epitope, wherein said library is constructed in a vector which expresses said target epitope in said host cells, wherein said host cells express a defined MHC molecule, and wherein said cytotoxic T-lymphocytes are restricted for said MHC molecule; and

(b) recovering those host cells which have undergone a lytic event.

E2
70. (Once Amended) The method of claim 68, further comprising:

Sub H3

E2

(a) isolating said vector from those host cells which have undergone a lytic event;

(b) transferring said vector to a population of host cells, wherein said vector expresses said target epitope in said host cells, and wherein said host cells express a defined MHC molecule;

(c) contacting said host cells with cytotoxic T-lymphocytes specific for said target epitope and restricted for said MHC molecule, under conditions wherein a host cell expressing said target epitope will undergo a lytic even upon contact with said T-lymphocytes; and

(d) recovering those host cells which have undergone a lytic event.

Sub H3

E3 Sub H4

79. (Once Amended) The method of claim 76, wherein said vector further comprises a transcriptional control signal in operable association with said heterologous nucleic acid molecules, and wherein said transcriptional control signal functions in a poxvirus.

80. (Once Amended) The method of claim 79, wherein said transcriptional control signal comprises a promoter.

E4

86. (Once Amended) The method of claim 79, wherein said transcriptional control signal comprises a transcriptional termination signal.

EA

87. (Once Amended) The method of claim 79, wherein said vector further comprises
a translational control signal associated with said transcriptional control signal.

ES

89. (Once Amended) The method of claim 87, wherein said translational control
signal comprises a translation initiation codon operably linked to said heterologous nucleic
acid molecules.
